Isatuximab improves on standard of care treatments for multiple myeloma

pharmafile | June 3, 2019 | News story | Sales and Marketing |  Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma 

Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in patients with multiple myeloma.

The Phase 3 ICARIA-MM trial found that isatuximab in combination with pomalidomide and dexamethasone showed statically significant improvements compared to pomalidomide and dexamethasone (pom-dex) alone.

Overall response rate to the isatuximab combination therapy was 60% compared to 35% for pom-dex alone. Meanwhile the median progression free survival for the isatuximab combo was 11.53 months compared to 6.47 months for pom-dex alone.

“Isatuximab in combination with pomalidomide and dexamethasone resulted in an impressive 40% reduction in the risk of progression or death compared to pomalidomide and dexamethasone alone,” said Dr Paul Richardson, principal investigator and clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute.

“This outcome is noteworthy because this trial included a particularly difficult-to-treat, relapsed and refractory patient population that was, in my view, highly reflective of real-world practice.”

Louis Goss